Collegium Pharmaceutical Inc., of Canton, Mass., appointed Douglas Carlson vice president of business development...EntreMed Inc., of Rockville, Md., appointed Ken K. Ren CEO, and added James Huang and Y. Alexander Wu to its board

Teva Pharmaceutical Industries Ltd., of Jerusalem, appointed Ivana Magovcevic-Liebisch senior vice president and head of corporate business development...Vermillion Inc., of Austin, Texas, appointed Thomas McLain president and CEO

Juventas Therapeutics Inc., of Cleveland, named Paul Resnick vice president of business development...Rexahn Pharmaceuticals Inc., of Rockville, Md., named Peter D. Suzdak CEO and Chang AHN chief scientist

Advaxis Inc., of Princeton, N.J., appointed Daniel J. O'Connor senior vice president, chief legal and business development officer...Relypsa Inc., of Redwood City, Calif., added Paul J. Hastings and David W.J. McGirr to its board

ImmunoCellular Therapeutics Ltd., of Los Angeles, named Andrew Gengos president and CEO...Pfenex Inc., of San Diego, named Kristi Sarno director of business development

Alimera Sciences Inc., of Atlanta, appointed Philip Ashman senior vice president and European managing director and named Eric Teo vice president and European medical director...Anne-Marie Swift will serve as vice president and European marketing director...Ohr Pharmaceuticals Inc., of New York, added Jeffrey S. Heier and Daniel Roth to its scientific advisory board

OthoCyte Corp., a subsidiary of BioTime Inc., of Alameda, Calif., appointed Francois Binette vice president of research and business development...Pharmalink AB, of Stockholm, Sweden, named Heather Cook director of regulatory affairs and Marek Poszepczynski director of business development

Cerecor Inc., of Baltimore, appointed James Vornov senior vice president, clinical development and regulatory affairs, and John Kaiser vice president of commercialization and business development...Fate Therapeutics Inc., of San Diego, appointed Christian Weyer president and CEO

DCPrime BV, of Amsterdam, the Netherlands, named Marcel Zwaal CEO and Anthony Hall chief medical officer...Theratechnologies Inc., of Montreal, appointed Luc Tanguay interim president and CEO...Zyngenia Inc., of Gaithersburg, Md., added Christian Itin and Jason Rhodes to its board

EffRx Pharmaceuticals SA, of Freienbach, Switzerland, appointed Lorenzo Bosisio vice president, head of business development and marketing...Ventrus Biosciences Inc., of New York, appointed JP Benya vice president, commercial operations and business development

Imprimis Pharmaceuticals Inc., of Solana Beach, Calif., added Lee S. Simon and Allan Green to its science and regulatory advisory board...Islet Sciences Inc., of New York, added Kevan Herold and Morton Printz to its scientific advisory board...Kinex Pharmaceuticals LLC, of Buffalo, N.Y., named Patrick Gallagher vice president, business development and investor relations

Eli Lilly and Co., of Indianapolis, named Michael Harrington senior vice president and general counsel...VacInnate Corp., of Cranbury, N.J., appointed Christine Mayer vice president of business development and Katalin Abraham vice president of regulatory affairs

he will chair the audit committee and serve on the compensation committee...Elcelyx Therapeutics Inc., of San Diego, named Mark Wiggins senior vice president of business development and added Ginger Graham to its board...Nile Therapeutics Inc., of San Mateo, Calif., named Darlene Horton president and CEO, and director

Mark Oki senior vice president, finance and chief financial officer...Bioniche Life Sciences Inc., of Belleville, Ontario, appointed James Rae independent chairman of its board and named Michael Rubin vice president, business development

Oncothyreon Inc., of Seattle, named Guy Cipriani vice president, business development...Quanterix Corp., of Lexington, Mass., named Paul Chapman president and CEO

NovImmune SA, of Plan-Les-Ouates, Switzerland, added Michael Steinmetz to its board and appointed David Slack head of corporate and business development...Xenetic Biosciences plc, of London, added Subash Kapre and Thomas Ulich to its scientific advisory board

Solvo Biotechnology Inc., of Budapest, Hungary, named William Johnson vice president, global operations and Kent Grindstaff senior director, business development and operations, North America

Gilead Sciences Inc., of Foster City, Calif., appointed Paul Boateng and Hannah Kettler to its health policy advisory board...Macrocure, of Petach Tikva, Israel, named Nissim Mashiach president and CEO...ViaCyte Inc., of San Diego, appointed Paul Laikind president and CEO

Oncobiologics Inc., of Cranbury, N.J., appointed Stephen McAndrew vice president, business development and Vincent Benn vice president, clinical and regulatory affairs...Paratek Pharmaceuticals Inc., of Boston, appointed Dennis Molnar CEO and director and Evan Loh chief medical officer and board chairman